Rituximab (anti-CD20) ( DrugBank: Rituximab )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 53 | シェーグレン症候群 | 1 |
53. シェーグレン症候群
臨床試験数 : 283 / 薬物数 : 320 - (DrugBank : 101) / 標的遺伝子数 : 56 - 標的パスウェイ数 : 181
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00363350 (ClinicalTrials.gov) | August 2006 | 10/8/2006 | Rituximab Treatment in Sjogren's Syndrome | Rituximab for the Treatment of Primary Sjögren's Syndrome: a Double Blinded Randomized Placebo-Controlled Trial | Sjogren's Syndrome | Drug: rituximab (anti-CD20) | University Medical Centre Groningen | Hoffmann-La Roche | Completed | 18 Years | 85 Years | Both | 30 | Phase 1/Phase 2 | Netherlands |